Evidence map›Paper›PMID 22700853›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2012

Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.

Vijaya Karoor, Mysan Le, Daniel Merrick, Karen A Fagan, Edward C Dempsey, York E Miller

Open access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 40 citations in OpenAlex.

  1. [Research Advances in Obstructive Sleep Apnea and Lung Cancer Comorbidity].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014
    Article
  17. Article
  18. Update in lung cancer and mesothelioma 2012.American journal of respiratory and critical care medicine · 2013
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Vijaya KaroorDepartment of Medicine, University of Colorado Denver, Denver, CO, USA.
Mysan Le
Daniel Merrick
Karen A Fagan
Edward C Dempsey
York E Miller
University of Colorado Denver · USDenver VA Medical Center · USUniversity of Colorado Cancer Center · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8M
VRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1M
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancerR01CA164780 · NCI · UNIVERSITY OF COLORADO DENVER · PI TUDER, RUBIN M. · 2011 to 2014
$2.3M
Neprilysin Apoptosis and Hypoxic Pulmonary HypertensionR01HL078927 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI DEMPSEY, EDWARD CHARLES · 2005 to 2008
$1.5M
NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA058187NCI NIH HHS P50 CA58187NCI NIH HHS R01 CA164780NHLBI NIH HHS HL14985NHLBI NIH HHS P01 HL014985NHLBI NIH HHS R01 HL078927NHLBI NIH HHS R01 HL078929
6 · The paper itself

Abstract

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk for the development of lung cancer, the mechanisms for which are incompletely understood. We hypothesized that the hypoxic pulmonary microenvironment present in COPD would augment lung carcinogenesis. Mice were subjected to chemical carcinogenesis protocols and placed in either hypoxia or normoxia. Mice exposed to chronic hypoxia developed tumors with increased volume compared with normoxic controls. Both lungs and tumors from hypoxic mice showed a preferential stabilization of HIF-2α and increased expression of VEGF-A, FGF2, and their receptors as well as other survival, proliferation, and angiogenic signaling pathways regulated by HIF-2α. We showed that tumors arising in hypoxic animals have increased sensitivity to VEGFR-2/EGFR inhibition, as chemoprevention with vandetanib showed markedly increased activity in hypoxic mice. These studies showed that lung tumors arising in a hypoxic microenvironment express increased growth, angiogenic, and survival signaling that could contribute to the increased lung cancer risk in COPD. Furthermore, the differential sensitivity of tumors arising in hypoxia to VEGFR-2/EGFR inhibition suggests that the altered signaling present in tumors arising in hypoxic lung might be therapeutically exploited in patients with underlying COPD.

Indexed as

AnimalsAntioxidantsBasic Helix-Loop-Helix ProteinsBiomarkers, TumorBlotting, WesternButylated HydroxytolueneCarcinogensCell ProliferationCytokinesEndothelial PAS Domain-Containing Protein 1Epithelial-Mesenchymal TransitionErbB ReceptorsFemaleHypoxiaImmunoenzyme TechniquesLung Neoplasms3-methylcholanthryleneAntioxidantsBasic Helix-Loop-Helix ProteinsBiomarkers, TumorButylated HydroxytolueneCarcinogensCytokinesEGFR protein, mouseEndothelial PAS Domain-Containing Protein 1ErbB ReceptorsMethylcholanthrenePiperidinesProto-Oncogene Proteins c-mycQuinazolinesUrethanevandetanibVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID22700853
PMCPMC4169262
OpenAlexW2163228689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.